Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Financial performance
Oncology
Financial review
Conclusion
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
canakinumab - IL-1 beta inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
NCT03447769 CANOPY-A (CACZ885T2301)
Adjuvant NSCLC
Phase 3
1500
Disease free survival (primary), overall survival (key secondary)
Canakinumab 200mg q3w sc for 18 cycles
Placebo q3w sc for 18 cycles
Patients with:
High-risk NSCLC (AJCC/UICC v.8 stage II-IIIA and IIIB (T>5cm N2)) after complete
resection and standard of care adjuvant cisplatin-based chemotherapy
All histologies
Read-out Milesstone(s)
Publication
2023
TBD
107 Investor Relations | Q3 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation